Marlborough, Mass., October 20, 2014—Lemelson Capital Management, a private investment management firm, today announced that it has taken a significant position in shares of Geospace Technologies (NASDAQ: GEOS). Lemelson Capital’s investment in Geospace Technologies, which will be held in the firm’s flagship Amvona Fund, represents approximately two percent of Geospace Technologies’ outstanding shares.
On October 16, 2014, Rev. Father Emmanuel Lemelson, Founder and President of The Lantern Foundation and Chief Investment Officer of Lemelson Capital Management, appeared on Benzinga's Pre-Market Prep show to discuss the recent sell-off in the market and long and short positions held by Lemelson Capital's top-performing Amvona Fund.
The Amvona Fund Ranked World’s Top Performing Long Bias Equity Fund for August 2014
Marlborough, Mass., October 2, 2014—Lemelson Capital Management, a private investment management firm, today announced that BarclayHedge, a global leader in fund performance ranking and assessment, has ranked The Amvona Fund as the world’s top-performing “long bias” fund for August 2014.
On September 16th, Rev. Father Emmanuel Lemelson, Founder and President of the Lantern Foundation, and Chief Investment Officer of Lemelson Capital Managements was invited onto Benzinga's Pre-Market Prep show to discuss Lemelson Capital's short and long stakes in shares of World Wrestling Entertainment (NYSE:WWE) for its clients.
Marlborough, Mass., September 5, 2014—Lemelson Capital Management, a private investment management firm, today marked the second anniversary of the launch of its flagship fund, The Amvona Fund, LP which has ranked repeatedly among the world’s top performing hedge funds. The firm also today released the overall and net gains for the fund since inception, which were, respectively, 257.74 percent and 160.21 percent. The fund’s performance since inception has outperformed the benchmark S&P 500 Total Returns Index by 209.07 percent (111.54 percent net of all fees and expenses).
Kulicke and Soffa accepts Lemelson Capital’s April 23rd, 2014 recommendation
Marlborough, Mass., August 27, 2014—Lemelson Capital Management, a private investment management firm, today commended the Board of Directors and management team of Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) for their favorable response to Lemelson Capital’s April 23, 2014 letter to CEO Bruno Guilmart urging the company to initiate a share repurchase program. In an announcement this morning, Kulicke and Soffa said its Board of Directors has authorized a repurchase of up to $100 million of the company’s common shares, effective immediately.
Ligand’s largest Shareholder BVF, Inc. sells 484,524 shares
A PDF version of the report is available here
Raising prospects for a continued deterioration in the stock price of Ligand Pharmaceuticals (NASDAQ: LGND), the largest shareholder in the company has moved to unload shares of the troubled company in a private transaction. Earlier this week, on August 19, BVF, Inc., the company’s largest shareholder, offloaded 484,524 shares in a private transaction, the terms of which are both costly and indicative of institutional sentiment.
Lemelson Capital short stake built as share price collapses on insolvency and bankruptcy risk
Rev. Father Emmanuel Lemelson, Founder and President of the Lantern Foundation and Chief Investment Officer of Lemelson Capital Management, appeared yesterday on Benzinga’s Pre-Market Prep show in which he addressed recent geopolitical and global market developments and the firm’s existing long and short investment positions, including Lemelson Capital’s short position in Ligand Pharmaceuticals (NASDAQ: LGND), which the firm first announced on June 16, 2014. Lemelson Capital has continued to sell the stock short even as its share price has collapsed over the last six weeks.
Lemelson Capital further increases short stake and reaffirms 100 percent downside risk in Ligand Pharmaceuticals (NASDAQ: LGND), revenue and earnings down across the board, while liabilities and dilution continue to rise dramatically.
A PDF version of the report is available here
Lemelson Capital further increases short stake and reaffirms 100% downside risk in Ligand Pharmaceuticals (NASDAQ: LGND), ancillary applications for Promacta® and Kyprolis® not commercially viable, Duavee® sales remain immaterial
A PDF version of the report is available here.
Please read the full disclosures at the end of the report by clicking on the link below.
Disclosure: Lemelson Capital is short shares of (NASDAQ:LGND).
A PDF version of Lemelson Capital's full 25-page report is available here.
LCM also released its May 2014 results with a 22.26% (16.29% net) YTD showing against 4.97% for the benchmark S & P 500 Total return index, which includes dividends.
Activist Positions in World Wrestling Entertainment (WWE) and Kulicke and Soffa Industries (KLIC) Fuel Gains
Marlborough, MA, May 27, 2014—Lemelson Capital Management, LLC, a private investment management firm, today announced that The Amvona Fund, LP has again been ranked by Barron's as one of the world's top performing hedge funds for April 2014. It represents the third time in eight months that Barron's monthly performance rankings of global hedge funds has included The Amvona Fund among the world's top performers. This designation follows the magazine previously ranking the fund as the top performing hedge fund for July and October 2013.
Ongoing Losses, Operating Failures, Material Misstatements Warrant and Require Urgent Executive Management Changes or a Sale of the Company